Axokine for Type II diabetes in obese patients and uncomplicated obesity, in trials, NT3 trials, three different BDNF trials (Regeneron, Amgen-Regeneron, & Sumitomo), at least one Cytokine trap to be in the clinic in 2000, significant angiogenesis research, and more. Add to this, a solid balance sheet, P&G support, Amgen support, long term agreement/relationship to manufacture intermediate for Merck, Roy Vagelos (former Chairman of the Board and Chief Executive Officer of Merck & Co.) at the helm, 1998 revenues of over 45 million and a market cap of only about 180 million.
Roy how about the next time you go to a Prudential board of directors meeting, you ask if Ralph Acompora would like to come visit and have a jelly donut or maybe a cream filled. I'm not sure how much Ralph really knows, but people seem to like his opinion and he looks like he likes donuts. Analyst are a little slow so a donut or two might be helpful/necessary. It would seem that some coverage might not be too far down the road.